Tetsuro Araki ^{1) 2) 3)} , Norihiko Iwazaki ^{1) 4)} , Naoki Ishiguro ^{1) 5)} , Atsushi Sakamoto ^{1) 5)} , Keisuke Nagata ^{1) 6)} , Masato Ohbuchi ^{1) 7)} , Hiroyuki Moriguchi ^{1) 7)} , Makiko Motoi ^{1) 8)} , Raku Shinkyo ^{1) 8)} , Toshiki Homma ^{1) 9)} , Sakae Sakamoto ^{1) 9)} , Yumiko Iwase ^{1) 2) 10)} , Ryota Ise ^{1) 11)} , Yasuharu Nakanishi ^{1) 12)} , Masahiro Uto ^{1) 12)} , Tomoaki Inoue ^{1) 2) 13)}
1) Consortium for Safety Assessment using Human iPS Cells (CSAHi) , 2) Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association , 3) Laboratory for Safety Assessment and ADME, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation , 4) DMPK Research Laboratories, Mitsubishi Tanabe Pharma Corporation , 5) Pharmacokinetics and Non-Clinical Safety, Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Ltd. , 6) Drug Safety Research Laboratories, Astellas Pharma Inc. , 7) Analysis & Pharmacokinetics Research Laboratories, Astellas Pharma Inc. , 8) Drug Metabolism and Pharmacokinetics Japan, Tsukuba Research Laboratories, Eisai Co., Ltd. , 9) Kissei Pharmaceutical Co., Ltd. , 10) Mitsubishi Tanabe Pharma Corporation , 11) Shin Nippon Biomedical Laboratories, Ltd. , 12) Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd. , 13) Safety Assessment Department, Research Division, Chugai Pharmaceutical Co., Ltd.